You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

November 12, 2012

Food Health Claims: Challenges for ASEAN Manufacturers

Informed Counsel

Within the food industry, all eyes are currently turned toward the European Union, because after December 14, 2012, new limitations will be introduced for acceptable health claims on food products.

Regulation No. 1924/2006 of the European Parliament and of the Council of December 20, 2006, on Nutrition and Health Claims Made on Foods (the Regulation) has changed the scope of the interpretation of health claims in the European Union. Initially, each country was entitled to have its own set of acceptable claims, but growing inconsistencies between countries made it difficult for manufacturers to sell their products.

European Regulation

In an attempt to harmonize the rules, the Regulation was adopted. It defined health claims as “any claim that states, suggests, or implies that a relationship exists between a food category, a food or one of its constituents and health” (Article 2 Definition 5). Such claims should not:

  • “Be false, ambiguous, or misleading.
  • Give rise to doubt about the safety and/or the nutritional adequacy of other foods.
  • Encourage or condone excess consumption of food.
  • State, suggest, or imply that a balanced and varied diet cannot provide the appropriate quantities of nutrients in general. . . .
  • Refer to changes in bodily functions which could give rise to or exploit fear in the consumer . . .”

As these restrictions are common in most countries in the world, they are not the reason why companies have raised concerns about this Regulation. The key issue is that the Regulation has provided specific conditions with regard to health claims applicable to products launched in Europe. For example, health claims will only be permitted if certain information is included in the labeling, presentation, or advertising, such as “a statement indicating the importance of a varied and balanced diet and healthy lifestyle” or “the quantity of the food and pattern of consumption required to obtain the claimed beneficial effect.”

The Regulation has set up a process by which companies are able to submit their proposed health claims for approval by the Commission. However, companies must submit generally accepted scientific evidence and ensure that the claim can be well understood by the average consumer. Of the 44,000 claims submitted, only 222 had been approved as of May 2012 according to Commission Regulation No. 432/2012, which established a list of permitted health claims made on foods, except for those claims referring to the reduction of disease or disease risk and to children’s development and health.

Surprisingly, some claims that were widely used in the past and approved by several national health agencies have been rejected, such as claims regarding prebiotics and probiotics products. The arguments raised by the Commission were that the scientific evidence provided by the submitting companies was not sufficient for this type of product. The main industries affected are currently raising their concerns with the Commission.

ASEAN Perspective

For companies set up within ASEAN, implementation of the Regulation will have a significant impact. Although most countries follow Codex Alimentarius and its Guidelines for use of Nutrition and Health Claims, discrepancies still exist between member countries as ASEAN has not yet implemented harmonized legislation on this particular topic. For example, a Malaysian company planning to sell its products in Thailand, Singapore, and the EU would face three different sets of requirements as some countries have even implemented a positive list of nutrition function claims. In another example, Thailand would not accept other function claims, contrary to Malaysia and Singapore, while the Singaporean authorities would authorize a disease risk reduction claim which would not be admissible in Malaysia or in Thailand.

Focusing on the examples of Thailand, Malaysia, and Singapore helps to highlight the differences among the interpretations of health claims in ASEAN, and thus the difficulties encountered by ASEAN companies to sell their products both within the region and overseas.

Thailand Experience

In Thailand, health claims are not described as clearly in legal terms compared to the EU, and interpretation is generally on a case-by-case basis. Section 40 of the Food Act refers indirectly to heath claims and states that “no one shall advertise the benefits, qualities, or efficacies of foods which are false or which are misleading, without getting prior approval from the Thai Food and Drug Administration (FDA).” The Notices of the FDA regarding “Bases on Food Advertisement” provide the requirements for food advertisements and for some specific food categories. However, only nutrition claims have specific acceptable guidelines in place set up by the Thai FDA (Notification of the Ministry of Public Health (MoPH) No. 182 of 1998 re: Nutrition Labeling).

An order of the Thai FDA No. 403/2551 (2008), “Consideration for Granting Permission to Make Health Claims for Probiotics in Food Products,” states that health claims are authorized for such products if they are backed with scientific evidence sufficient for the permission to use these types of claims. For other products, such as weight control products and other products falling into the Specially Controlled Food category, the process is similar, but might be more cumbersome.

Additionally, the first regulation specially targeting health claims has recently been implemented, and health claims for probiotics were clarified in the Notification of the MoPH regarding “Use of Probiotics in Food” dated June 27, 2011. A health claim means “a displaying of a picture, photograph, invented mark, mark, trademark, or any statement on the label which is related to the food, food components, or nutrients concerned with health, either directly or indirectly.”

Thus, it is interesting to observe that Thailand currently has, in practice, a recognized, strict approach toward health claims on food products. But contrary to the EU, Thailand still accepts most health claims for probiotic products if they are supported by scientific journals. Although a draft of the Notification on the Advertisement of Food will soon be published in the Government Gazette, there does not yet seem to be a move toward narrowing the types of claims  acceptable for food products. A notification regarding “Health Claims and Warnings” and an announcement regarding “Scientific Substantiation of Health Claims” are also in the early stages of the drafting process.

Malaysia Experience

The Malaysian Food Act of 1983, supported by the Food Regulation of 1985, amended in 2005 to encompass health and nutrition claims, is the main source of legislation in Malaysia covering health claims. Within ASEAN, Malaysia is the only country that makes nutrition labeling a requirement. A Guide to Nutrition Labeling and Claims has also been issued to assist companies in their advertisement process in Malaysia. Malaysia follows the Codex Alimentarius Guidelines for Use of Nutrition and Health Claims more closely than many other countries.

As in most ASEAN countries, nutrient claims and, more specifically, content claims, comparative claims, and nutrient function claims, are acceptable. There are no specific regulations on prebiotics and probiotics in Malaysia. Ingredients are permitted for use in health supplements and conventional food, but approval is required beforehand. Thus, prebiotics and probiotics claims are acceptable if such claims fall into the authorized claims by the Ministry of Health (e.g., “Bifidobacteria lactis helps foster a beneficial intestinal environment and may help to reduce the incidence of diarrhea”). The requirements for submitting a claim involve submitting sufficient scientific evidence (which includes five clinical trial approvals from other recognized countries), as well as ensuring that the claim is comprehensible for consumers.

Singapore Experience

The Singapore Food Regulations, supported by the Guide to Food Labeling and Advertisements, implement the scope of acceptability of health claims in Singapore. Under article 9 of the Food Regulations, false or misleading statements, words, brands, pictures, or marks purporting to indicate the nature, stability, quantity, strength, purity, composition, weight, origin, age, effects, or proportion of the food or any ingredients are not allowed to be used on food labels and advertisements, unless otherwise specified. Singapore also prohibits the use of:

  • Claims for therapeutic or prophylactic action.
  • Claims which could be interpreted as advice of a medical nature from any person.
  • Claims that a food will prevent, alleviate, or cure any disease or condition affecting the human body.
  • Claims that health or an improved physical condition may be achieved by consuming any food.

One particularity of Singapore is that risk-related claims are acceptable; similarly, in the EU, a list of acceptable nutrient function claims has been implemented. In order to obtain approval, a company would have to establish, among other requirements, that essential nutrients with established recommended intakes are of nutritional importance, and that the claim is sufficiently generally accepted by the scientific community and is understandable to consumers.

The Guide to Food Labeling and Advertisements also includes the acceptability of the claim, “prebiotics promote the growth of good Bifidus bacteria to help maintain a healthy digestive system.” Thus, like in Thailand, claims on probiotics and prebiotics are acceptable. Companies can also state that a product “helps to suppress/fight against harmful bacteria in the digestive system, thereby helping to maintain a healthy digestive system.”

Future Expectations

Clearly, ASEAN companies are faced with a challenge if each country in which they are planning to sell their products requires different analysis and/or proof of their claims.

The Codex Alimentarius (prepared jointly by the United Nations and the World Health Organization) and the World Trade Organization, among others, are working toward harmonizing the rules. ASEAN countries have prepared a set of guiding principles for food control systems, which include the Common Guidelines for the Labeling of Prepackaged Foodstuffs.

Another step toward harmonization was taken recently. In early September 2012, the ASEAN countries announced that they have agreed in principle to impose uniform standards in regard to health claims. The objective is to implement these regulations by 2015, but a draft is not yet available.

As these regulations begin to develop, companies in the food industry should approach the relevant government agencies and try to participate in the drafting of the new standards. One of the significant points of discussion will be to ensure the complete harmonization of claims for prebiotics and probiotics products. It is important for the industry to learn the lessons of the EU Regulation and to work closely with regulators to ensure that the harmonized rules have a reasonable degree of continuity with the currently accepted interpretations.

RELATED INSIGHTS​ 

February 26, 2026
Laos’ Food and Drug Department (FDD) has been using a new online registration system for drugs since the beginning of the year. The system, which was implemented following the November 2025 issuance of Notice No. 5960/FDD, became the official pathway for submissions on January 1, 2026. Since that date, paper-based registrations have no longer been accepted. This marks a significant advancement in the digitalization of regulatory processes in Laos. As the online system is now the exclusive platform for registration, renewal, and amendments, companies that have not yet aligned their processes to the new system should act promptly to ensure a smooth transition. To assist with this, the FDD will conduct periodic training sessions on the use of the online registration system, which will be delivered either in person or remotely, depending on operator demand. To start using the system, drug and medical device manufacturers, as well as import-export companies, that have not yet registered must submit a formal request identifying the authorized personnel who will access the platform, after which they will be issued user accounts and access codes. Each request must be accompanied by the company’s enterprise registration certificate (incorporation certificate), a copy of the identity card or passport of each designated user, and a scanned copy of their signature. There is no restriction on the number of users per company, allowing flexibility to meet operational needs. Companies that already hold accounts and access codes from the trial phase may continue using them and may apply for additional accounts if needed. Additional Requirements The new system also introduces a standardized format for drug registration numbers. For example, an import drug registration number such as 06 I 4040/15 will be changed to 06-IM-04040-15, and a domestic drug registration number such as 06 L 4040/15 will be changed to
January 21, 2026
Spurred by global geopolitics and Canada’s Indo-Pacific Strategy, which aims to forge deeper ties with ASEAN, Canadian companies have been showing growing interest in Thailand and Southeast Asia in recent years. To understand the opportunities offered by the region, we sat down with Andrew Stoutley, a Toronto native and the chief operating officer of Tilleke & Gibbins, a leading Southeast Asian regional law firm with over 130 years of history in Thailand. Q: Why are Canadian companies looking at Thailand and Southeast Asia right now? A: Two reasons stand out. First, diversification has moved up the agenda. Many Canadian companies want options outside North America due to tariff volatility and policy uncertainty in the United States, as well as questions around the next Canada–United States–Mexico Agreement mandatory joint review. At the same time, the shift of global production from China to Southeast Asia is accelerating, driven by rising costs, geopolitics, and the need to avoid overreliance on a single market. As a result, Canadian companies are looking for a second production base or a regional hub, and Thailand and its neighbors are natural choices given their manufacturing depth, location, and established supply chains. Second, Canada’s own efforts in the region are gaining traction. The Indo-Pacific Strategy has led to more on-the-ground support, including larger trade missions, upgraded diplomatic posts, and new financing options. Export Development Canada (EDC) now has a presence in Bangkok, giving Canadian companies a direct line to financing and insurance in Thailand. There’s also steady progress on trade frameworks like the recently signed Canada–Indonesia Comprehensive Economic Partnership Agreement (which will come into effect pending domestic procedures), ongoing negotiations of a Canada–ASEAN FTA, and the exciting announcement about the launch of negotiations of a Canada–Thailand FTA. Together, these developments have the potential to make it much easier
January 8, 2026
Thailand’s approach to cannabis regulation has moved quickly from broad access to a medical, prescription‑only system. The latest government regulation classifies the cannabis flower as a controlled herb under the Thai Traditional Medicine Wisdom Act. The latest rules ban advertising and recreational sales, allow sales only to patients with prescriptions (up to 30 days), and require flowers to come from GACP‑certified (Good Agricultural and Collection Practices) farms. More importantly, cannabis dispensaries can only sell to patients presenting valid prescriptions issued by one of seven professions—medical doctors, Thai traditional practitioners, applied Thai traditional practitioners, traditional Chinese medicine practitioners, pharmacists, dentists, and folk healers—consistent with approved clinical indications. Noncompliance risks license suspension or revocation, and criminal penalties of up to one year’s imprisonment or a THB 20,000 fine. The dispensary‑only model that proliferated in Thailand in recent years is expected to end soon, as the rules will push all cannabis dispensaries into medical settings or retail pharmacies. Dispensaries must convert into medical establishments—clinics, pharmacies, or traditional pharmacies—complete with on‑site licensed practitioners as well as budtenders; strong controls for storage, hygiene, odor, and smoke; and facilities for record-keeping. All flowers dispensed or exported must come from GACP‑certified farms. If the government ends dispensaries outright and forces a conversion to clinics or pharmacies, compensation will not be automatic at the outset. As a result, business operators should plan for compliance and repurposing under the Medical Facilities Act, Modern Drug Act, and Herbal Product Act, which regulate medical clinics, modern pharmacies, and traditional medicine pharmacies, respectively. The table below summarizes the required licenses for clinics, pharmacies, and traditional medicine pharmacies selling cannabis flowers in Thailand. Aside from the specific listed licenses, all three types of establishments must also obtain a license to sell a controlled herb (cannabis flowers) from the Department of Thai Traditional
January 6, 2026
On December 30, 2025, Thailand’s Electronic Transactions Development Agency (ETDA) notified digital marketplace operators of a consolidated list of “high‑risk products” that are subject to strict monitoring on digital platforms. The list was jointly prepared by the Thai Industrial Standards Institute (TISI) and the Food and Drug Administration (FDA) to guide platform compliance in the initial phase of implementation of the Electronic Transaction Committee’s Notification on Other Measures for Marketplace for Goods with Specific Characteristics under Section 18(2) of the 2022 Royal Decree on Digital Platform Businesses Requiring Notification B.E.2568 (2025). The notice is addressed to operators of digital platform services that function as product marketplaces with specific characteristics laid out in the notification. The ETDA states that the TISI and the FDA are closely monitoring the high‑risk product categories on digital platforms, and the published list serves as the baseline reference for platform screening during the initial phase of the notification’s implementation. High‑Risk Product List The list aggregates categories of products that are illegal to sell online or are otherwise tightly regulated under Thai law, with an emphasis on health-related products, controlled substances, medical devices, and a wide range of industrial products that require certification or compliance with specified Thai Industrial Standards, as detailed below. Prohibited and tightly controlled health products. This includes all categories of modern medicines subject to control other than general household remedies; all categories of controlled herbal products except for over-the-counter herbal products; narcotics; psychotropic substances; and medical devices requiring use in medical facilities or a physician’s prescription. Selected industrial products requiring heightened controls. The list highlights dozens of TISI-regulated items commonly sold online. Examples include pacifiers, rice cookers, electrical wire, food wrap film, crayons, washing machines and dryers, air conditioners, electric cookers and air fryers, water heaters, microwave ovens, LED luminaires, hair dryers